Pitango HealthTech announces first closing of new $175 million fund
The new fund has already made several investments, including in QuantHealth.ai, an AI company focused on clinical trial simulations to accelerate and de-risk drug development, and Nevia Bio, a FemTech company developing an AI-based biomarker platform for early detection of women’s health diseases
Pitango HealthTech, Pitango VC's dedicated healthcare fund, announced on Wednesday the first closing of its second dedicated healthcare fund, Pitango HealthTech II. Pitango HealthTech II, a $175 million fund, will invest in healthcare innovation, including the decentralization of healthcare, personalized medicine, medical devices and diagnostics, as well as artificial intelligence, software and data infrastructure.
The new fund has already made several investments, including in QuantHealth.ai, an AI company focused on clinical trial simulations to accelerate and de-risk drug development, and Nevia Bio, a FemTech company developing an AI-based biomarker platform for early detection of women’s health diseases.
Pitango HealthTech invests in companies from seed to commercial stage. The fund’s investment strategy is focused on all segments of healthcare and life sciences. Previous investments include companies such as Protai, Laguna Health, Vertos, Visby, Clew and Magenta.
“Despite the global and local macroeconomic challenges, the healthcare sector continues to show resilience and growth. Recent events such as the pandemic, decentralization of healthcare, and value-based care, have resulted in unprecedented openness towards the adoption of new technologies,” said Ittai Harel, Managing Partner at Pitango HealthTech. “We’re launching this new fund to continue to back entrepreneurs and invest in companies that are revolutionizing the healthcare industry. Pitango believes that the most promising healthcare innovations occur at the convergence of life science and medical technologies with data science and AI, coupled with innovative services. This revolution is at its early onset, and is yet to accelerate.”
Related articles:
The Pitango HealthTech team is made up of Ittai Harel (Managing Partner), Hila Karah (Managing Partner), Dr. Jonathan Glazer (Partner), Joel Schoppig (Senior Principal) and Dr. Seth Rudnick (Special Advisor).
Pitango HealthTech is part of the Pitango investment platform, operating alongside Pitango First and Pitango Growth Funds. Since its inception in 1993, Pitango has invested in over 250 companies and seen more than 85 become publicly traded companies, or acquired by strategic players.
